6 January 2022 (Thursday) - Transfusion News Update

The nice people at Transfusion News sent their update today which focussed somewhat on sickle cell disease.

LentiGlobin Therapy for Sickle Cell Disease

January 4, 2022Sickle cell disease (SCD) is caused by a single point mutation in the β-globin gene and affects around 100,000 people in the U.S. SCD can be cured in 14-20% of younger patients who have an HLA-matched donor, but allogeneic hematopoietic stem-cell transplants also carry risk of graft-versus-host disease, graft rejection, and even death. [Read More]


Cost-Effectiveness of Transfusions to Prevent Silent Cerebral Infarcts in Children with Sickle Cell Disease

December 29, 2021 Guidelines published by the American Society of Hematology in 2020 recommend annual transcranial doppler ultrasound (TCD) screening to help identify silent cerebral infarcts in children with severe forms of sickle cell disease (SCD). In children with abnormal TCD screenings, the guidelines recommend transfusions every 3-4 weeks for at least a year to reduce the risk of further silent strokes. [Read More]


Outpatient COVID-19 Convalescent Plasma Reduces Hospitalizations

December 21, 2021 While more than 500,000 units of COVID-19 convalescent plasma (CCP) have been transfused in the United States alone, the use and efficacy has become controversial. The World Health Organization recently issued a recommendation that CCP should not be used outside of clinical trials. Almost all of the available randomized clinical trial data, however, are among individuals who were hospitalized. [Read More]

No comments:

Post a Comment